Comparison of uptake, prices of biosimilars in USA, Germany, Switzerland

JAMA Network

About The Study: The findings of this study suggest that more biosimilars have been marketed in Germany and Switzerland than in the United States. Policies that counter anticompetitive practices in the United States could allow biosimilars to enter the market sooner and could also lower health care costs with improved access. Awareness of biosimilars should be promoted to increase uptake of biosimilars globally.

Authors: Kerstin N. Vokinger, M.D., J.D., Ph.D., L.L.M., of the University of Zurich in Zurich, Switzerland, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.44670)

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.